Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in North America:
Eisai Company Limited
sales of $5.42 billion
of which 49%
was Pharmaceutical Business -Japan),
of which 50%
was International), and
Perrigo Company PLC
of which 51%
Grifols SA reported sales of $5.29 billion
December of 2018.
increase of 7.5%
versus 2017, when the company's sales were $4.92 billion.
This was the third consecutive year of growth at Grifols SA.
Sales of Bio Supplies saw an increase
that was more than double the company's growth rate: sales were up
158.6% in 2018, from
$76.08 million to $196.77 million.
Grifols SA also saw significant increases in sales in
Hospital (up 23.4% to $140.75 million)
Others/raw Materials (up 27.2% to $26.45 million)